Add To Watchlist
Share URL
Edwards Lifesciences Corporation
EW: NYSELowest reading is at 9 out of 100. All scores are out of 100.
About The Company
CEO
Mr. Bernard J. Zovighian
Market Cap
49.74 Billion USD
Sector
Healthcare
Website
https://www.edwards.comLast Update
27/09/2026, 09:19:11
Description
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally.
Read More
Strongest readings
- ✔Altman-Z score of 11.52 sits above the distress range
- ✔Financial health is strong (health score 92 out of 100)
- ✔Debt is low at 0.06 times equity
- ✔Share count has been falling at 1.24% per year
- ✔Return on capital employed of 10.64% is above the market average of 10.00%
Weakest readings
- ✘Earnings have fallen this year (-69.33%)
- ✘Revenue is growing at 11.55% per year while free cashflow is falling
- ✘Returns on capital have declined over five years (7.10% lower)
- ✘Price-to-earnings of 40.1 is above the market average of 19.6
- ✘Priced well above the cashflow it produces (value score 9 out of 100)
Key Figures
| Status | Metric | Value | Reading | Market avg |
|---|---|---|---|---|
| ✘ | Price / earnings (TTM) | 40.13x | 19.60x | |
| ✘ | Margin of safety (DCF) | -78.44% | 17.95% | |
| ✔ | Revenue growth (5y average) | 11.55% | 10.97% | |
| ✘ | Dividend yield (TTM) | 0.00% | 1.85% | |
| ✔ | Share count, per year | -1.24% | 0.00% | |
| ✔ | Return on capital employed | 10.64% | 10.00% |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
Valuation
9 / 100Priced above the market on most measures.
| Status | Metric | Value | Reading | Market avg |
|---|---|---|---|---|
| ✘ | Price / earnings | 40.13x | 19.60x | |
| ✘ | Free cashflow yield | 2.66% | 4.70% | |
| Price / earnings growth | N/A | 1.50x | ||
| Price / book | 4.64x | — | ||
| ✘ | Margin of safety | -78.44% | 17.95% |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
- ✘Estimated intrinsic value of 18.61 USD is below the current price of 86.29 USD
Desired Margin Of Safety
0%
▼
Tip: Set your desired Margin Of Safety
Free Cash Flow Type
Annual Cashflow Growth
0%
Discount Rate
0%
Estimated Fair Value: 35.6 USD ✘
Current Price: 86.3 USD
How Does This Work?
Show Advanced Options
This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated fair value for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel for the impact this has on longterm investment returns and find a margin of safety you are comfortable with.
Growth
25 / 100Growing more slowly than the market on most measures.
| Status | Metric | Value | Reading | Market avg |
|---|---|---|---|---|
| ✔ | Revenue growth | 11.55% | 10.97% | |
| ✘ | Earnings growth | 2.07% | 14.48% | |
| ✘ | Cashflow growth | -30.77% | 12.35% |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
- ✔Revenue growth has improved this year (17.25% against a five year average of 11.55%)
- ✘Earnings growth has slowed this year (-69.33% against a five year average of 2.07%)
- ✔Free cashflow growth has improved this year
- ✘Revenue is growing at 11.55% per year while free cashflow is falling at 30.77% per year
Health
92 / 100Balance sheet covers its obligations.
Measured on Leverage and capital, Funding and liquidity, Earnings quality.
| Status | Metric | Value | Reading | Threshold |
|---|---|---|---|---|
| ✔ | Altman-Z score | 11.52 | 3.00 | |
| ✔ | Piotroski score | 6.00 | 5.00 | |
| ✔ | Debt / equity | 0.06x | 0.80x | |
| ✔ | Current ratio | 3.72x | 1.00x | |
| ✔ | Interest coverage | 61.97x | 2.50x | |
| ✔ | Free cashflow / debt | 2.23x | 0.15x | |
| ✔ | Debt / capital | 0.05x | 1.00x |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
Management
54 / 100Returns on capital are at or above the market.
| Status | Metric | Value | Reading | Market avg |
|---|---|---|---|---|
| ✘ | Return on equity | 10.38% | 15.00% | |
| ✔ | Return on capital employed | 10.64% | 10.00% | |
| Return on assets | 7.84% | — | ||
| Free cashflow return on capital | 11.23% | — | ||
| ✘ | Return on capital, 5y change | -7.10% | 0.00% | |
| ✔ | Share count, per year | -1.24% | 0.00% | |
| ✔ | Share count, recent | -1.44% | 0.00% | |
| ✘ | Realized buyback return | -42.70% | 0.00% | |
| ✔ | Goodwill erosion / equity | 1.13% | 2.00% | |
| Price volatility, 5 year | 33.78% | — |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
- ✘Shares were repurchased while the value score was only 9 out of 100
Analysts
not enough data| Status | Metric | Value | Reading | Neutral |
|---|---|---|---|---|
| Analyst opinion score | N/A | 50 |
The bar shows how good a reading is, so a longer bar is always better. The tick marks the benchmark.
Financial History
Annual figures across the full reporting history we hold.
Market Peers
EW
SEC Filings
Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.
See 35+ Years Annual ReportsOther Information
Company Name
Edwards Lifesciences Corporation
Currency
USD
Beta
0.852
Vol Avg
3879498
Ceo
Mr. Bernard J. Zovighian
Cik
0001099800
Cusip
Exchange
NYSE
Full Time Employees
16000
Industry
Medical Devices
Sector
Healthcare
Ipo Date
Address
One Edwards Way
City
Irvine
State
CA
Country
United States
Zip
92614
Phone
949 250 2500
Analysis Last Updated
27/09/2026, 09:19:11
Financial data compiled from SEC EDGAR filings and Yahoo Finance.